BACKGROUND: This study was conducted to determine whether any regulatory single-nucleotide polymorphism (SNP) in an inflammatory gene was associated with a high symptom burden in patients 1 year after the diagnosis of multiple myeloma (MM). METHODS: MM patients rated symptoms with the MD Anderson Symptom Inventory multiple myeloma module (MDASI-MM) and provided buccalswab DNA samples. SNPs for 4 cytokine genes (interleukin 6 [IL6] 2174G>C, IL1b 2511C>T, tumor necrosis factor a [TNFa] 2308G>A, and IL10 21082G>A) were tested. Logistic regression models were used to identify SNPs that might predict moderate/severe symptoms (rated 4 on the MDASI-MM 0-10 scale). For the evaluation of the relationship between SNPs and overall symptom burden, a 2-step cluster analysis was used to divide patients into subgroups with high or low symptom levels. RESULTS: Forty-one percent of the 344 patients enrolled had a high overall symptom burden. The most prevalent moderate/severe symptoms were fatigue (47%), pain (42%), numbness (38%), and bone aches (32%). For non-Hispanic whites, the IL1b 2511 CC genotype was associated with a high overall symptom burden (odds ratio [OR], 2.35; 95% confidence interval [CI], 1.25-4.72; P 5.004), whereas the IL6 2174 GG genotype predicted less moderate/severe fatigue (OR, 0.53; 95% CI, 0.29-0.88; P 5.013). For other patients, the IL6 2174 GG genotype predicted moderate/severe pain (OR, 3.36; 95% CI, 1.23-13.64; P 5.010). CONCLUSIONS: These results support growing evidence showing that inflammation is associated with cancer-related symptoms, and they suggest that racial/ethnic factors contribute to this association.
INTRODUCTION
Multiple myeloma (MM) is the second most prevalent hematological malignancy. 1 Significant progress has been achieved in the treatment of MM in recent decades. [2] [3] [4] High-dose chemotherapy with stem cell transplant (SCT) has improved diseasefree survival and overall survival in comparison with conventional melphalan-prednisone chemotherapy. 5 However, this increased longevity and longer disease course often result in a distinct symptom burden that substantially reduces healthrelated quality of life. 6 Therefore, identifying individual MM patients at risk for a high symptom burden that could influence treatment planning would be potentially beneficial for both patients undergoing active therapy and disease-free survivors.
Recent research findings suggest that genetic disposition may influence a patient's experience of cancer-and treatment-related symptoms and health-related quality of life. 7, 8 Inflammation is a candidate mechanism underlying the expression of cancer-related symptoms. 9, 10 We have demonstrated a significant association between symptom outcomes and circulating cytokines (interleukin 6 , tumor necrosis factor a [TNF-a], and soluble TNF receptor 1) during aggressive cancer treatments such as allogeneic or autologous hematopoietic SCT 11, 12 and chemoradiotherapy. 13, 14 Polymorphisms in proinflammatory and anti-inflammatory cytokine genes, particularly in regulatory regions, have been linked to intra-individual variations in cytokine production: the C allele of the 2174G>C single-nucleotide polymorphism (SNP) in the IL6 promoter region has been related to significantly lower levels of plasma IL-6 in healthy subjects, 15 the 2511C>T polymorphism of IL1b has biological relevance in the regulation of IL-1 production, 16 and the 2308G>A polymorphism in the promoter region of the TNFa gene increases the expression of TNF-a. 17 These SNPs have also been correlated with the risk for MM, 18, 19 and this suggests the necessity of addressing how disease development is involved in the gene-symptom association.
Evidence of gene-symptom associations is limited but emerging. Cytokine gene polymorphisms have been associated with cancer-related symptoms and toxicities in patients with cancer, 20, 21 but to our knowledge, they have not been studied in MM. Furthermore, higher incidence and mortality rates of MM among blacks 22 indicate the need to consider racial differences when one is studying the symptom burden related to MM development and/or treatment.
The objectives of this study were to identify a subset of MM patients with a higher risk for persistent symptom burden and to determine whether any regulatory SNP in a cytokine gene was associated with such a high symptom burden. We focused on SNPs in genes encoding cytokines that have been linked at the protein level to symptoms reported in cancer patients, including IL6 2174G>C (rs1800795), IL1b 2511C>T (rs16944), and TNFa 2308G>A (rs1800629). Another SNP, IL10 21082G>A (rs1800896), is associated with varied expression of IL-10, 23 whose SNPs have been linked to pain in lung cancer survivors. 21 We hypothesized that alleles related to increased proinflammatory cytokine expression (G of IL6 2174, C of IL1b 2511, and G of TNFa 2308) and the allele related to decreased antiinflammatory cytokine expression (G of IL10 21082) would be risk alleles for a high symptom burden in MM patients.
MATERIALS AND METHODS
For this prospective, cross-sectional study, MM patients were consecutively recruited from November 2011 to March 2013 at the outpatient clinics of the Departments of Lymphoma/Myeloma and Stem Cell Transplantation at The University of Texas MD Anderson Cancer Center in Houston, Texas. Eligible patients had a confirmed pathological diagnosis of MM for at least 12 months before enrollment, were at least 18 years old, and were in clinical follow-up or therapy. The study was approved by the MD Anderson institutional review board. All participants gave written informed consent.
Patient characteristics and clinical parameters (age, sex, cancer stage, Eastern Cooperative Oncology Group performance status, body mass index, comorbid conditions, years since MM diagnosis, previous SCT, previous radiotherapy, current maintenance therapy, and anemia status) were recorded by research staff.
Multisymptom Assessment
Patients provided self-reported ratings of symptom severity upon enrollment. The psychometrically validated MD Anderson Symptom Inventory multiple myeloma module (MDASI-MM) assesses the severity of 13 common cancer-related symptoms from the core MD Anderson Symptom Inventory 24 and 7 additional MM-specific symptoms (bone aches, muscle weakness, sore mouth/ throat, rash, difficulty concentrating, constipation, and diarrhea). 25 Patients rate their symptom severity over the previous 24 hours on a 0 to 10 scale ranging from "not present" to "as bad as you can imagine." Six items related to symptom interference with function are rated over the previous 24 hours on a 0 to 10 scale ranging from "did not interfere" to "interfered completely."
SNP Assay
Patients provided buccal-swab samples upon enrollment. Isohelix SK-2S DNA buccal swabs (Cell Projects, Ltd, Harrietsham, United Kingdom) were used to collect DNA samples 26 at least 1 hour after patients ate, drank, or cleaned their teeth. The Gentra Puregene blood kit (Qiagen, Venlo, the Netherlands) was used for the purification of archive-quality DNA from buccal cells. 27 Purified DNA was stored at 280 C for later genotyping. Polymerase chain reaction (PCR) was performed as previously described. 28, 29 For IL6 2174G>C, 219-base pair (bp) PCR products were digested with NlaIII (New England Biolabs, Ipswich, Mass) at 37 C overnight; the G allele was uncut, and the C allele was cut into 126-and 93-bp bands. For IL1b 2511C>T, 348-bp PCR products were digested with Bso BI (New England Biolabs) at 37 C overnight; the T allele was uncut, and the C allele was cut into 184-and 164-bp bands. For IL10 G>A and TNFa 2308 G>A, restriction fragment length polymorphism genotyping was performed as previously described. 28, 29 Positive and negative controls were used in each genotyping assay, and 10% of samples were randomly selected and assayed in duplicate. The concordance between duplicates was 100%.
Statistical Analysis
We dichotomized single symptoms into none/mild (rated 0-3 on the MDASI-MM's 0-10 scale) and moderate/ severe (rated 4-10). 30 To evaluate the overall symptom burden, we applied the SPSS 2-step cluster analysis. 31 In step 1, using patients' ratings for 20 MDASI-MM symptoms, we created preclusters of patients by constructing a cluster feature tree algorithm. In step 2, preclusters were merged with agglomerative hierarchical clustering. The optimal number of clusters was determined with Schwarz's Bayesian information criterion. We expected 2 groups of patients with either high or low symptom levels. To confirm that 2-step clustering effectively differentiated patients according to their symptom burden, we used the Student t test and Cohen's d effect size to compare the severity of individual symptoms between the high-and lowsymptom groups. We expected the 2-step clustering to generate subgroups of patients with distinct levels of symptoms with at least a medium effect size (Cohen's d: 0.2, small; 0.5, medium; and 0.8, large). 32 Considering the possibility of differences related to race/ethnicity, 33, 34 we first examined the genotype distribution of the 4 SNPs among race/ethnicity groups and found significant differences by group. We therefore stratified patients by race/ethnicity (non-Hispanic white vs other) in the remaining analyses. We conducted logistic regression analyses to identify the genetic factors for single symptoms (moderate/severe vs none/mild) and overall symptom burden (high vs low), and we controlled for demographic and clinical confounders (age, sex, cancer stage, Eastern Cooperative Oncology Group performance status, body mass index, comorbid conditions, years since MM diagnosis, previous SCT, previous radiotherapy, current maintenance therapy, and anemia status). To clarify the association between SNPs, disease development, and symptom burden, we controlled for the disease status (tumor response) in all models. Stepwise selection was used to identify the optimal models, and odds ratios (ORs) were estimated for the effect size of associations between SNPs and symptoms. The Hosmer-Lemeshow test of the goodness of fit 35 was performed to see whether the model fit the data. A bootstrap resampling technique 36, 37 with 1000 bootstrap samples was applied for internal model validation, and this provided a bias-corrected estimate of the 95% confidence intervals (CIs) of the ORs. Bonferroni correction was used for multiple comparisons of the 4 SNPs with a 5 .013 (.05/4).
RESULTS

Patient and Treatment Characteristics
Three hundred sixty-three eligible patients were approached; 3 declined to participate, 16 had incomplete symptom assessments (>50% of MDASI-MM items were missed), and the remaining 344 were included in the analysis. Table 1 presents patient demographic and clinical characteristics. All enrolled patients contributed buccal samples and symptom data. Most had received autologous SCT (81%), and 58% were still undergoing MM maintenance therapy. Non-Hispanic white was the most prevalent race/ethnicity (65%), and it was followed by black (22%) and Hispanic (9%). Approximately half (44%) of the patients reported 1 comorbidities, and one-fourth of the patients (23%) had stage III disease.
Symptom Patterns and Severities
The 5 most severe symptoms were fatigue (mean, 3.4 6 2.8), pain (3.2 6 3.1), numbness (2.8 6 2.9), bone aches (2.3 6 2.9), and drowsiness (2.1 6 2.6). No significant differences in the total symptom score were found between non-Hispanic whites (1.4 6 1.1) and other racial groups (1.6 6 1.4, P 5 .073). The percentages of patients reporting moderate/severe (4) symptom levels were as follows: 47% for fatigue, 42% for pain, 38% for numbness, 32% for bone aches, 27% for drowsiness, 27% for dry mouth, 27% for disturbed sleep, and 26% for muscle weakness. Two-step clustering generated 2 groups: a lowsymptom group (n 5 203 or 59%) and a high-symptom group with significantly higher mean symptom severity (n 5 141 or 41%). Table 2 presents the average scores for all MDASI-MM symptom items and the 5 most severe individual symptoms by the symptom severity group. As expected, all symptom scores differed significantly between the high-and low-severity groups (P < .001, t test). Effect sizes (Cohen's d) of differences between the high-and low-symptom groups for all symptom and interference items exceeded 0.8, and this indicated a large magnitude of effect.
SNP Profiles and Associations with Symptoms
Except for the TNFa 2308 SNP, all examined SNPs showed different genotype frequencies by race/ethnicity. Patients who were non-Hispanic white showed higher frequencies of the IL6 2174 CC, IL1b 2511 CC, and IL10 21082 GG genotypes than all other races (Table 3) . Thus, we dichotomized the study population by race/ethnicity (non-Hispanic white vs others) for all analyses with SNP data.
After we controlled for all demographic and clinical factors and other cytokine SNPs, logistic regression modeling indicated that in comparison with patients with an IL1b 2511 CT or TT genotype, those with the CC genotype in the non-Hispanic white population demonstrated double the risk for experiencing a high overall symptom burden and moderate/severe pain (OR, 2.35; 95% CI, 1.25-4.72; P 5 .004). This result was not replicated in other races. The IL6 2174 GG genotype showed diverse associations with moderate/severe symptoms by ethnic group. Non-Hispanic whites with the GG genotype were less likely to report moderate/severe fatigue (OR, 0.53; 95% CI, 0.29-0.88; P 5 .013), whereas in Original Article patients other than non-Hispanic whites, the GG genotype predicted moderate/severe pain (OR, 3.36; 95% CI, 1.23-13.64; P 5 .010; Table 4 ). Other than SNPs, comorbidities and an Eastern Cooperative Oncology Group performance status 1 were both predictors of a high overall symptom burden and moderate/severe levels of the top 5 symptoms. Table 5 shows the associations between SNPs and individual symptoms. The goodness-of-fit test results were insignificant, and this suggested that the models fit the data well (Table 6) .
DISCUSSION
One year after the diagnosis and the initial treatment for MM, approximately 40% of the patients in this study experienced moderate/severe symptoms, with fatigue, pain, numbness, drowsiness, and bone aches being the most severe. We identified host genetic factors linked to inflammation as potential risk factors for a higher symptom burden. A high-cytokine expression genotype (IL1b 2511 CC) was predictive of moderate/severe symptoms and a high overall symptom burden for non-Hispanic white patients but not for other patients. The other high-cytokine expression genotype (IL6 2174 GG) was predictive of moderate/severe fatigue, pain, and numbness in patients other than non-Hispanic whites.
The prevalence and etiology of MM-related symptoms are poorly understood, and risk factors for a high symptom burden have not been determined. This finding builds on our studies and those of others reporting circulating proinflammatory cytokines with a symptom burden in patients with cancer. 11, 13, 14 Although research has found a positive association between critical circulating cytokines and multiple symptoms related to cancer therapy, few studies have examined this association at a host genetic background level, and the results from these few studies are controversial. For example, the IL6 2174 and TNFa 2308 polymorphisms were independently associated with fatigue in breast cancer survivors. 20 The IL1b 2511 CC genotype was associated with fatigue severity in 171 breast cancer survivors, 20 but this association was not observed in a larger sample (n 5 302) of breast cancer survivors with chronic and persistent fatigue 38 or in prostate cancer patients. 39 In lung cancer survivors, 2 other polymorphisms of IL1b were associated with fatigue. 21 Our results from a mixed sample of MM patients are the first to show that expression of the regulatory SNP IL1b 2511C>T is associated with multiple symptoms and overall symptom burden. IL1b participates in activating T cells and induces IL-6 Abbreviations: CI, confidence interval; IL, interleukin; OR, odds ratio; TNFa, tumor necrosis factor a. There were no results for nausea and vomiting because too few patients reported moderate/severe levels of these symptoms.
in fibroblasts, endothelial cells, keratinocytes, and peripheral blood monocytes. 40 The association between the expression of a regulatory SNP, 16 
IL1b
2511C>T, and symptom burden not only supports inflammation as a major pathway underlying cancerrelated symptoms but also provides a candidate marker for individualized symptom management. However, the complex mechanisms underlying symptom development as a result of acute and chronic illness and cancer therapy-induced toxicities suggest the need for a broader search of genetic markers in all potential pathways and for the evaluation of the interactive effects of those markers with carefully selected phenotypes.
Unlike similar studies that treated race/ethnicity as a covariate 20, 41 or that included participants of a single race, 21 we dichotomized our study population by race/ ethnicity into non-Hispanic white and other groups because of differences in allelic frequency among races. We found different associations between SNPs and multiple symptoms by racial/ethnic group, and this suggests that those polymorphisms have race-specific effects in modulating symptoms. Racial/ethnic associations with host genetic variations have been found in the development of cancers 42 but have never been addressed in genesymptom association studies. Studies using data from the Surveillance, Epidemiology, and End Results project indicate that MM incidence and mortality rates demonstrate significant racial differences. For example, compared with non-Hispanic whites, blacks had a much higher concentration of patients younger than 65 years and a much lower concentration of patients older than 75 years. 43 The significant effects of the IL6 2174 polymorphism in predicting major symptoms (fatigue, pain, and numbness) in other patients (primarily black patients) suggest that race/ ethnicity-specific biomarkers should be considered when personalized symptom management strategies are being developed, especially for younger black MM patients who have better overall survival. 43 This study had several limitations. First, although a significant association between 1 SNP and symptom burden was found for non-Hispanic whites, the small sample sizes of the other racial/ethnic groups, especially blacks, hindered our attempt to identify genetic risk factors in those groups. Our finding of racial/ethnic disparities should be interpreted with consideration of this limitation and should be verified in a larger population. In addition, validation of genetic associations in a subgroup of patients was not feasible with such a small sample. Although we used bootstrapping to estimate the CIs of effect sizes of SNP markers, the scientific credibility of the results still needs to be validated in a larger sample, with randomly generated subsample sets used for the initial screening of the SNPs and for confirmatory tests on those SNPs. Second, besides the 4 selected SNPs, there are other genetic variations that may modify multiple pathways underlying symptom development, and they should be considered in future research. Moreover, individualized symptom management will require genome-wide association studies to identify previously unknown genetic markers that may indicate novel biological pathways underlying gene-symptom associations. Third, the overall symptom burden based on all 20 symptoms may cause an underestimation of SNPsymptom associations because of insignificant relationships between SNPs and some symptoms; moreover, such clustering cannot identify genetic markers in different pathways. However, results from our studies of circulating inflammatory marker levels and the current genetic study both support the hypothesis that inflammation is a common underlying mechanism of cancerrelated symptom development. Finally, the patient's experience of symptoms will usually change during and after the course of cancer treatment, 44 and longitudinal associations between symptoms and circulating cytokines have been confirmed. 11 Future studies with longitudinal symptom assessments will clarify how cytokine gene markers modulate symptom change during treatment and into survivorship. In conclusion, more than one-third of MM patients experienced a significant symptom burden after the initial year of standard anticancer treatment in this study. Non-Hispanic whites with the high-expression variant of IL1b and other patients with the high-expression variant of IL6 may be at particular risk for a high symptom burden. These genetic markers and the consideration of each patient's racial/ethnic background could help to identify high-risk patients early in the treatment trajectory and could inform individualized symptom-management strategies during and after aggressive cancer treatment. Our results confirm previous findings on the potential contribution of the inflammatory pathway to cancer symptom development, and this could guide the design of targeted interventions to combat multiple symptoms experienced by patients with MM, whether they are induced by the cancer itself or by its treatment.
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